EBS Collar Strategy
EBS (Emergent BioSolutions Inc.), in the Healthcare sector, (Drug Manufacturers - Specialty & Generic industry), listed on NYSE.
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services.
EBS (Emergent BioSolutions Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a market capitalization of approximately $429.8M, a beta of 2.33 versus the broader market, a 52-week range of 5.31-14.06, average daily share volume of 883K, a public-listing history dating back to 2006, approximately 900 full-time employees. These structural characteristics shape how EBS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.33 indicates EBS has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a collar on EBS?
A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot.
Current EBS snapshot
As of May 15, 2026, spot at $7.98, ATM IV 68.80%, IV rank 4.87%, expected move 19.72%. The collar on EBS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this collar structure on EBS specifically: IV regime affects collar pricing on both sides; compressed EBS IV at 68.80% typically pushes the short call premium to roughly offset the long put cost, with a market-implied 1-standard-deviation move of approximately 19.72% (roughly $1.57 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated EBS expiries trade a higher absolute premium for lower per-day decay. Position sizing on EBS should anchor to the underlying notional of $7.98 per share and to the trader's directional view on EBS stock.
EBS collar setup
The EBS collar below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With EBS near $7.98, the first option leg uses a $8.38 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed EBS chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 EBS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $7.98 | long |
| Sell 1 | Call | $8.38 | N/A |
| Buy 1 | Put | $7.58 | N/A |
EBS collar risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium.
EBS collar payoff curve
Modeled P&L at expiration across a range of underlying prices for the collar on EBS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use collar on EBS
Collars on EBS hedge an existing long EBS stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
EBS thesis for this collar
The market-implied 1-standard-deviation range for EBS extends from approximately $6.41 on the downside to $9.55 on the upside. A EBS collar hedges an existing long EBS position with a protective put while financing the put cost via a short call; when the premiums roughly offset, the collar acts as a near-zero-cost insurance band around the current spot. Current EBS IV rank near 4.87% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on EBS at 68.80%. As a Healthcare name, EBS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to EBS-specific events.
EBS collar positions are structurally neutral (protective); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. EBS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move EBS alongside the broader basket even when EBS-specific fundamentals are unchanged. Always rebuild the position from current EBS chain quotes before placing a trade.
Frequently asked questions
- What is a collar on EBS?
- A collar on EBS is the collar strategy applied to EBS (stock). The strategy is structurally neutral (protective): A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot. With EBS stock trading near $7.98, the strikes shown on this page are snapped to the nearest listed EBS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are EBS collar max profit and max loss calculated?
- Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium. For the EBS collar priced from the end-of-day chain at a 30-day expiry (ATM IV 68.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a EBS collar?
- The breakeven for the EBS collar priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current EBS market-implied 1-standard-deviation expected move is approximately 19.72%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a collar on EBS?
- Collars on EBS hedge an existing long EBS stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
- How does current EBS implied volatility affect this collar?
- EBS ATM IV is at 68.80% with IV rank near 4.87%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.